Remote Assessment of Disease and Relapse in Central Nervous System Disorders


Start Date
End Date
IMI2 - Call 3
Grant agreement number

Type of Action: 
RIA (Research and Innovation Action)

IMI Funding
11 000 000
EFPIA in kind
13 580 029
1 132 081
Total Cost
25 712 110


The RADAR-CNS project aims to develop new ways of monitoring major depressive disorder, epilepsy, and multiple sclerosis using wearable devices and smartphone technology. The key goal of the project is to improve patients’ symptoms and quality of life and also to change how these and other chronic disorders are treated.

Epilepsy, depression, and multiple sclerosis are distinct disorders that affect 400 million people worldwide, with different causes and symptoms, all of which can be severely detrimental to patients’ quality of life and life expectancy. For all three disorders, patients often experience periods where their symptoms are manageable, followed by periods of deterioration and acute illness (relapse). Patient surveys have repeatedly highlighted the need to predict when relapses will happen and to improve the treatments which are available to stop them from occurring. Continuous remote assessment using smartphones and wearable devices provides a complete picture of a patient’s condition at a level of detail which was previously unachievable. Moreover, it could potentially allow treatment to begin before a patient’s health deteriorates, preventing the patient relapsing or becoming more ill before they seek treatment.

Achievements & News

RADAR-CNS MS study gets underway
July 2018

The RADAR-CNS project has recruited the first participants to the multiple sclerosis (MS) component of the project. The participants will wear a Fitbit device for up to 24 hours a day. This will capture information about mobility, heart rate and sleep quality.### In the following weeks, the participants will also receive a chest-worn device, the eFaros, which will be used for a week every three months to better characterise balance, gait variability, falls and heart rate variability. Professor Giancarlo Comi of the Vita-Salute San Raffaele University, Milan, Italy said: ‘We are very pleased to have recruited our first participant in Milan. It’s an exciting time for us as we enrol and recruit more people to our MS studies.’ In total, RADAR-CNS hopes to recruit 400 participants with MS to assess changes in disability and fatigue over time. In addition, the project will recruit 240 people with MS for a study on mood changes (in particular on depressive feelings) in people with a recent diagnosis of MS. Studies of patients with major depressive disorder and epilepsy got underway in 2017.

RADAR-CNS co-leader receives prestigious award in UK Honours
June 2018

Professor Matthew Hotopf, co-lead of IMI’s RADAR-CNS project, has been awarded a CBE (Commander of the Order of the British Empire) for services to psychiatric research in the Queen’s birthday honours list. ###The Queen’s honours recognise the achievements and service of a wide range of people. ‘I am deeply honoured to receive this award,’ said Professor Hotopf, who is Vice Dean of Research at Institute of Psychiatry, Psychology & Neuroscience at King’s College London and Director of the NIHR Maudsley Biomedical Research Centre. ‘It represents the contributions of a huge number of people in my research team working to improve the profile of mental health research and ultimately to benefit people with mental health problems.’ Professor Hotopf's research explores the interaction between mental and physical health. He has worked extensively in areas where mental health relates to other walks of life – including military health, mental health law, and epidemiological studies on the impact of mental disorders. The RADAR-CNS project aims to develop new ways of monitoring major depressive disorder, epilepsy, and multiple sclerosis using wearable devices and smartphone technology.

RADAR-CNS platform wins award at Bio-IT World Conference & Expo
May 2018

A research platform developed by IMI’s RADAR-CNS project has won a ‘Best of Show’ award in the data integration and management category at the Bio-IT World Conference & Expo in Boston, US in May. RADAR-CNS is working to develop new ways of measuring major depressive disorder, epilepsy and multiple sclerosis (MS) using wearable devices and smartphone technology. ###The project’s open source RADAR-base platform allows RADAR-CNS study participants to share their health data (e.g. from sensors and questionnaires) with clinicians and researchers in a secure way, keeping identifiable data local while linking to other non-identifiable data centrally. ‘RADAR-base provides an exciting, unique opportunity to empower research with data from both medical-grade and consumer-grade devices,’ said RADAR-base project lead Amos Folarin of King’s College London. ‘RADAR-base gives researchers and device manufacturers a place to build open systems to share, manage, host, and actually use these data to support the next generation of healthcare.’

RADAR-CNS recruits first participants in depressive disorder study
January 2018

IMI’s RADAR-CNS project has recruited the first participants in the depression component of its study. The aim of RADAR-CNS is to develop new ways of measuring major depressive disorder, epilepsy and multiple sclerosis (MS) using wearable devices and smartphone technology. ###The first depression study participants have now received FitBit Charge 2 devices as well as smartphone apps. The participants will wear the FitBit for up to 24 hours a day, allowing it to capture information on their heart rate, sleep quality, and physical activity levels. Every few weeks, they will answer a short series of questions via the RADAR-CNS apps. Faith Matcham, post-doctoral research associate at RADAR-CNS, hopes to recruit around fifty more people over the coming months. ‘We’re so excited to be starting recruitment – this study will provide important information about how useable the RADAR-CNS platform is, as well as providing us with data which might be invaluable for improving our understanding of the course of major depression,’ she said. The epilepsy component of the study got underway in June last year, and the project team hopes to start recruitment for the multiple sclerosis study soon.

Participants Show participants on map

EFPIA companies
  • Biogen Idec Limited, Maidenhead, Berkshire, United Kingdom
  • H. Lundbeck As, Valby, Denmark
  • Janssen Pharmaceutica Nv, Beerse, Belgium
  • Msd It Global Innovation Center Sro, Prague, Czech Republic
  • Ucb Biopharma Sprl, Brussels, Belgium
Universities, research organisations, public bodies, non-profit groups
  • Charite - Universitaetsmedizin Berlin, Berlin, Germany
  • Consorcio Centro De Investigacion Biomedica En Red M.P., Madrid, Spain
  • Fundacio Hospital Universitari Vall D'Hebron - Institut De Recerca, Barcelona, Spain
  • Katholieke Universiteit Leuven, Leuven, Belgium
  • King'S College London, London, United Kingdom
  • Northwestern University, Evanston, Illinois, United States
  • Provincia Lombardo Veneta - Ordineospedaliero Di San Giovanni Di Dio- Fatebenefratelli, Brescia, Italy
  • Region Hovedstaden, Hilleroed, Denmark
  • Stichting Imec Nederland, Eindhoven, Netherlands
  • Stichting Vumc, Amsterdam, Netherlands
  • The University Of Nottingham, Nottingham, United Kingdom
  • Universita' Degli Studi Di Bergamo, Bergamo, Italy
  • Universita Vita-Salute San Raffaele, Milano, Italy
  • Universitaet Augsburg, Augsburg, Germany
  • Universitaetsklinikum Freiburg, Freiburg, Germany
  • Universitat Passau, Passau, Germany
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Gabo:Mi Gesellschaft Fur Ablauforganisation:Milliarium mbH & Co. KG, Munich, Germany
  • Intel Corporation (Uk) Limited, Swindon, United Kingdom
  • Software AG, Darmstadt, Germany
  • Stichting Lygature, Utrecht, Netherlands
Third parties
  • Fundacio Sant Joan De Deu, Esplugues de Llobregat, Spain
  • Ospedale San Raffaele SRL, Milano, Italy
  • The Hyve BV, Utrecht, Netherlands


Project coordinator
Project leadership
Vaibhav A. Narayan
Janssen Research & Development